<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in most cases develops after chemotherapy of other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and shows characteristic chromosome aberrations </plain></SENT>
<SENT sid="1" pm="."><plain>Two general types of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> have previously been identified </plain></SENT>
<SENT sid="2" pm="."><plain>One type is observed after therapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and characteristically presents as therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> with deletions or loss of the long arms of chromosomes 5 and 7 or loss of the whole chromosomes </plain></SENT>
<SENT sid="3" pm="."><plain>The other type is observed after therapy with <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> and characteristically presents as overt t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with recurrent balanced chromosome aberrations </plain></SENT>
<SENT sid="4" pm="."><plain>Recent research suggests that these 2 general types of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics </plain></SENT>
</text></document>